成人骨肉瘤患者接受两药方案治疗的长期生存:FSG-GETO的OSAD93 II期研究最终结果
OSAD93是一项多中心II期研究,评估成人局限性高级别骨肉瘤术前不接受多柔比星、仅用异环磷酰胺(IFO)联合顺铂(CDDP)的疗效,术后对残留肿瘤细胞>10%者加用多柔比星。60例患者中位随访322个月,5年、10年、25年无病生存率分别为51.8%、49.9%、47.8%,总生存率分别为64.4%、64.4%、55.9%,主要终点未达到,但长期生存良好且毒性有限。
要点
- 术前SHOC方案(IFO 9 g/m2联合CDDP 100 mg/m2第4天给药)共4周期,术后对残留肿瘤细胞>10%者加用多柔比星(HOCA方案)。
- 良好组织学反应(残留肿瘤细胞≤10%)见于16/60(27.5%)患者,主要终点未达到。
- 中位随访322个月,25年无病生存率47.8%、总生存率55.9%,未观察到长期心脏毒性。
核心结论
- 尽管OSAD93的主要终点未达到,这一术前不含多柔比星的方案在局限性骨肉瘤中带来了良好的长期生存且毒性有限。
研究设计与样本
- 这是一项多中心II期研究,纳入局限性高级别骨肉瘤患者,接受术前IFO联合CDDP化疗。
- 患者接受4周期术前化疗:IFO 9 g/m2、CDDP 100 mg/m2于第4天给药(SHOC方案),随后局部治疗。
- 术后对残留肿瘤细胞>10%的患者加用多柔比星(HOCA方案)。
- 主要目标为良好组织学反应(残留肿瘤细胞≤10%)在>30%患者中达到;次要目标为无病生存(DFS)、总生存(OS)和毒性。
- 1994年1月至1998年6月共纳入60例患者,中位年龄27岁(范围16-63岁)。
主要发现
- 原发肿瘤部位为肢体者76%、躯干/头/颈部者24%。
- SHOC周期中3-4级中性粒细胞减少伴发热、血小板减少和再住院分别发生于58%、17%、17%和22%的周期;HOCA周期中分别发生于76%、28%、47%和47%的周期。
- 良好组织学反应见于16/60(27.5%)患者。
- 中位随访322个月,5年DFS和OS分别为51.8%和64.4%。
- 10年DFS和OS分别为49.9%和64.4%;25年DFS和OS分别为47.8%和55.9%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RATIONALE: We report a phase II trial (OSAD93) testing CDDP with ifosfamide (IFO), without doxorubicin in neoadjuvant phase, in adult osteosarcoma with a 25 years follow-up. PATIENTS AND METHODS: This is a multicentric phase II study of neoadjuvant chemotherapy with IFO and CDDP in localized high-grade osteosarcoma of patients. Patients received 4 pre-operative courses of IFO 9 g/m2 and CDDP 100 mg/m2 on day 4 (SHOC regimen), followed by local treatment. Doxorubicin was added post-operatively (HOCA regimen) in patients with > 10 % residual tumor cells. A Good Histological Response (GHR), ie ≤ 10 % residual tumor cells in > 30 % of patients, was the primary objective. Disease-free survival (DFS), overall survival (OS) and toxicity were secondary objectives. RESULTS: From Jan 1994 to Jun 1998, 60 patients were included. Median age was 27 (range: 16-63). Primary tumor sites were limbs (76 %), trunk, head or neck (24 %). After neoadjuvant SHOC, grade 3-4 and febrile neutropenia, thrombopenia, and re-hospitalization occurred in 58 %, 17 %, 17 % and 22 % of SHOC courses and in 76 %, 28 %, 47 %, 47 % of HOCA courses, respectively. GHR was obtained in 16/60 (27.5 %) patients. With a median follow-up of 322 months, the DFS and OS were 51.8 % and 64.4 % at 5 years. At 10 years, DFS and OS were 49.9 % and 64.4 %. At 25 years, DFS and OS were 47.8 % and 55.9 %. No long-term cardiac toxicity was observed. Three patients developed a second malignancy (one fatal) after 300 months. CONCLUSION: Though the primary endpoint of OSAD93 was not met, this pre-operative doxorubicin-free regimen led to excellent long-term survival with limited toxicity in localized osteosarcoma.
引用
- Blay JY, Penel N, Toulmonde M, et al. Long term survival in adult osteosarcoma patients treated with a two-drug regimen: Final results of the OSAD93 phase II study of the FSG-GETO. Eur J Cancer. 2024. PMID: 39018632. doi:10.1016/j.ejca.2024.114228
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。